Novo Nordisk has its sights on becoming a major player in heart disease
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Lots of news on the cardiovascular front this morning: We discuss Novo Nordisk’s plans in heart disease, and Verve’s gene editing therapy for familial hypercholesterolemia. We also learn about a new initiative to try and prevent gonorrhea spread with a meningitis vaccine.
Read Original Article: Novo Nordisk has its sights on becoming a major player in heart disease »
